FDA Provides Answers to Biologics License Questions
A guidance document answers questions regarding the transition of biologics applications from under the FD&C Act to the PHS Act.
FDA issued a Q&A document on March 4, 2020 that answers questions about the implementation of the transition of biologics applications from approval under the Federal Food, Drug, and Cosmetic (FD&C) Act to section 351 of the Public Health Service (PHS) Act. The transition is part of the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) and will begin on March 23, 2020.
Specifically, the document describes the types of products affected by the transition and provides information about application and license numbers; agency office review procedures; chemistry, manufacturing, and control changes; and other requirements. The agency also describes the labeling compliance policy for biologics license applications.
Source: FDA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
